Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.100 -0.240 (-2.88%)
Official Closing Price Updated: 8:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
39 40 Next >
10 Psychedelics CEOs To Pay Attention To In 2022
By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both... 
Via Benzinga
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31 
Via Benzinga
Advances in Precision Medicine Boost Research on Psychedelics
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From June 17, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 16, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From June 15, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics
Via Investor Brand Network
What You Should Know About Ego Death
Via Investor Brand Network
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a... 
Via FinancialNewsMedia
Psychedelic Stock Gainers And Losers From June 14, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44 
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS: 
Via Benzinga
WHO Wants Climate Change Efforts to Prioritize Mental Health
Via Investor Brand Network
Topics Climate Change
Exposures Climate
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, traders! We're starting off the week with a dive into the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
Cybin Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67 
Via Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE: TWTR) shares has been discus 
Via Benzinga
Four Key Takeaways from the Catalyst Summit in Canada
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investors! With another day starting comes another breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13 
Via Benzinga
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
New Study Suggests That MDMA May Decrease Fear, Boost PTSD Treatment
Via Investor Brand Network
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”)... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS